Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vunakizumab plus colchicine perioperative prophylaxis in tophus resection
ChiCTR2600116007Phase 4Not yet recruiting
- Sponsor
- The Fifth Hospital of Xi'an
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of vunakizumab in gout (2 arms), sponsored by The Fifth Hospital of Xi'an. Primary endpoint: Rate of acute gout attacks within 7 days after the surgery. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
vunakizumab
03
Conditions
gout
Beyond the preview
Go deeper on ChiCTR2600116007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600116007.